INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:IUI1 • US46120E6023

415.55 EUR
+4.55 (+1.11%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

IUI1 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 68 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IUI1 a very profitable company, without any liquidiy or solvency issues. IUI1 shows excellent growth, but is valued quite expensive already. These ratings would make IUI1 suitable for growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • IUI1 had positive earnings in the past year.
  • IUI1 had a positive operating cash flow in the past year.
  • Each year in the past 5 years IUI1 has been profitable.
  • Of the past 5 years IUI1 4 years had a positive operating cash flow.
IUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFIUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

1.2 Ratios

  • IUI1 has a better Return On Assets (14.19%) than 94.12% of its industry peers.
  • Looking at the Return On Equity, with a value of 16.12%, IUI1 belongs to the top of the industry, outperforming 83.82% of the companies in the same industry.
  • IUI1 has a Return On Invested Capital of 14.47%. This is amongst the best in the industry. IUI1 outperforms 91.18% of its industry peers.
Industry RankSector Rank
ROA 14.19%
ROE 16.12%
ROIC 14.47%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IUI1.DE Yearly ROA, ROE, ROICIUI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • IUI1 has a better Profit Margin (28.58%) than 98.53% of its industry peers.
  • In the last couple of years the Profit Margin of IUI1 has grown nicely.
  • IUI1 has a Operating Margin of 29.44%. This is amongst the best in the industry. IUI1 outperforms 98.53% of its industry peers.
  • In the last couple of years the Operating Margin of IUI1 has grown nicely.
  • IUI1 has a Gross Margin of 66.38%. This is in the better half of the industry: IUI1 outperforms 73.53% of its industry peers.
  • In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
Industry RankSector Rank
OM 29.44%
PM (TTM) 28.58%
GM 66.38%
OM growth 3Y4.46%
OM growth 5Y3.66%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
IUI1.DE Yearly Profit, Operating, Gross MarginsIUI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IUI1 is creating some value.
  • There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IUI1.DE Yearly Shares OutstandingIUI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IUI1.DE Yearly Total Debt VS Total AssetsIUI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.44
WACC10.08%
IUI1.DE Yearly LT Debt VS Equity VS FCFIUI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • IUI1 has a Current Ratio of 4.97. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
  • IUI1 has a better Current ratio (4.97) than 97.06% of its industry peers.
  • IUI1 has a Quick Ratio of 4.20. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
  • IUI1 has a better Quick ratio (4.20) than 97.06% of its industry peers.
Industry RankSector Rank
Current Ratio 4.97
Quick Ratio 4.2
IUI1.DE Yearly Current Assets VS Current LiabilitesIUI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.83%, which is quite impressive.
  • The Earnings Per Share has been growing by 21.42% on average over the past years. This is a very strong growth
  • Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 20.51%.
  • IUI1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.22% yearly.
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%

3.2 Future

  • Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.07% on average per year.
  • The Revenue is expected to grow by 12.31% on average over the next years. This is quite good.
EPS Next Y11.25%
EPS Next 2Y13.22%
EPS Next 3Y13.64%
EPS Next 5Y15.07%
Revenue Next Year15.2%
Revenue Next 2Y14.36%
Revenue Next 3Y13.92%
Revenue Next 5Y12.31%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IUI1.DE Yearly Revenue VS EstimatesIUI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
IUI1.DE Yearly EPS VS EstimatesIUI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 54.89, IUI1 can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 64.71% of the companies are valued more cheaply.
  • When comparing the Price/Earnings ratio of IUI1 to the average of the S&P500 Index (27.92), we can say IUI1 is valued expensively.
  • Based on the Price/Forward Earnings ratio of 49.35, the valuation of IUI1 can be described as expensive.
  • Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than 73.53% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.78. IUI1 is valued rather expensively when compared to this.
Industry RankSector Rank
PE 54.89
Fwd PE 49.35
IUI1.DE Price Earnings VS Forward Price EarningsIUI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • IUI1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 70.59% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 60.29% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 76.52
EV/EBITDA 47.39
IUI1.DE Per share dataIUI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of IUI1 may justify a higher PE ratio.
  • A more expensive valuation may be justified as IUI1's earnings are expected to grow with 13.64% in the coming years.
PEG (NY)4.88
PEG (5Y)2.56
EPS Next 2Y13.22%
EPS Next 3Y13.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IUI1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INTUITIVE SURGICAL INC

FRA:IUI1 (2/6/2026, 7:00:00 PM)

415.55

+4.55 (+1.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22
Earnings (Next)04-20
Inst Owners88.29%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap147.31B
Revenue(TTM)10.06B
Net Income(TTM)2.75B
Analysts77
Price Target531.45 (27.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)1.5%
PT rev (3m)1.81%
EPS NQ rev (1m)0.91%
EPS NQ rev (3m)1.17%
EPS NY rev (1m)0.11%
EPS NY rev (3m)4.97%
Revenue NQ rev (1m)1.05%
Revenue NQ rev (3m)0.97%
Revenue NY rev (1m)0.44%
Revenue NY rev (3m)2.29%
Valuation
Industry RankSector Rank
PE 54.89
Fwd PE 49.35
P/S 18.08
P/FCF 76.52
P/OCF 58.7
P/B 10.2
P/tB 10.41
EV/EBITDA 47.39
EPS(TTM)7.57
EY1.82%
EPS(NY)8.42
Fwd EY2.03%
FCF(TTM)5.43
FCFY1.31%
OCF(TTM)7.08
OCFY1.7%
SpS22.98
BVpS40.75
TBVpS39.92
PEG (NY)4.88
PEG (5Y)2.56
Graham Number83.31
Profitability
Industry RankSector Rank
ROA 14.19%
ROE 16.12%
ROCE 16.61%
ROIC 14.47%
ROICexc 28.65%
ROICexgc 29.85%
OM 29.44%
PM (TTM) 28.58%
GM 66.38%
FCFM 23.63%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y4.46%
OM growth 5Y3.66%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 111.36%
Cap/Sales 7.17%
Interest Coverage 250
Cash Conversion 85.84%
Profit Quality 82.69%
Current Ratio 4.97
Quick Ratio 4.2
Altman-Z N/A
F-Score8
WACC10.08%
ROIC/WACC1.44
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
EPS Next Y11.25%
EPS Next 2Y13.22%
EPS Next 3Y13.64%
EPS Next 5Y15.07%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
Revenue Next Year15.2%
Revenue Next 2Y14.36%
Revenue Next 3Y13.92%
Revenue Next 5Y12.31%
EBIT growth 1Y36.82%
EBIT growth 3Y22.63%
EBIT growth 5Y22.55%
EBIT Next Year34.54%
EBIT Next 3Y22.15%
EBIT Next 5Y20.8%
FCF growth 1Y287.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.61%
OCF growth 3YN/A
OCF growth 5YN/A

INTUITIVE SURGICAL INC / IUI1.DE FAQ

Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?

ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.


Can you provide the valuation status for INTUITIVE SURGICAL INC?

ChartMill assigns a valuation rating of 1 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.


Can you provide the profitability details for INTUITIVE SURGICAL INC?

INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 8 / 10.


Can you provide the financial health for IUI1 stock?

The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 7 / 10.